Biotech Co. Dodges Shareholder Suit Over 'Hyped' Drugs
A New York federal judge on Wednesday freed Cellceutix Corp. from a proposed shareholder class action alleging that the biotechnology company fraudulently hyped two of its drugs to inflate stock prices,...To view the full article, register now.
Already a subscriber? Click here to view full article